TC BioPharm (Holdings) plc American Depositary Shares - TCBP STOCK NEWS

TC Biopharm (NASDAQ: TCBP) has received equity research coverage from EF Hutton, which issued a 'Buy' rating with a target price of $5. This rating follows TC Biopharm's key milestones, including successful Phase 1b/2a trial results in late-stage Acute Myeloid Leukemia (AML) patients treated with allogeneic gamma-delta T cells and the granting of orphan drug status for its product OmnImmune® in AML. The company focuses on developing gamma-delta T cell therapies for cancer and has a robust pipeline and significant intellectual property portfolio.

TC Biopharm announced that it has received MHRA and Research Ethics Committee approvals to begin clinical trials for its OmnImmune® therapy to treat Acute Myeloid Leukemia (AML). The Phase 2/3 trials are set to start enrollment in the first half of 2022 in the UK, with plans to expand into the US afterward. Previously, OmnImmune® received orphan drug designation from the FDA. CEO Bryan Kobel expressed enthusiasm about progressing with their proprietary therapy following promising Phase 1b/2a results. The company is focused on developing gamma-delta T cell therapies with a strong pipeline for future indications.

On March 17, 2022, TC Biopharm (NASDAQ: TCBP) announced that the FDA granted orphan drug status to its lead product, OmnImmune®, for treating Acute Myeloid Leukemia (AML). This designation allows for a seven-year exclusive marketing period post-approval, enhancing commercial protection for OmnImmune®. The company aims to advance OmnImmune® through Phase 2b/3 trials, leveraging its innovative allogeneic gamma-delta T cell therapies. TC Biopharm positions itself at the forefront of cancer therapy development, with plans for enrollment in trials in both the UK and the US.

TC Biopharm (NASDAQ: TCBP) announced a significant enhancement of its intellectual property (IP) portfolio, which includes 6 granted patents and 45 pending applications related to gamma-delta T cell therapies. The IP covers revolutionary 'co-stimulatory' CAR-T cells aimed at lessening toxicity and expanding targeted therapy options. CEO Bryan Kobel emphasized the importance of this portfolio in establishing a competitive edge and advancing clinical development. The company continues to file additional applications, indicating a commitment to innovation in cancer and viral treatment therapies.

TC Biopharm announced positive interim results from its Phase 1a/2b study of TCB-002, OmnImmune®, targeting relapse/refractory Acute Myeloid Leukemia (AML). Out of 7 treated patients, 50% in the higher dose cohort achieved complete responses, with no serious safety concerns reported. The study evaluated safety and tolerability, indicating OmnImmune® is a promising therapeutic option for late-stage AML patients. The company plans to expand trials in 2022 and report further data, highlighting the potential of gamma-delta T cell therapies in treating blood cancers.

TC Biopharm, a clinical-stage biotechnology company, will host a corporate update call on March 8, 2022, at 9:00 am ET. The call will focus on recent milestones, corporate developments, and clinical plans, with CEO Bryan Kobel facilitating the event. Investors are encouraged to submit questions ahead of time at IR@tcbiopharm.com. The company, known for its innovative allogeneic gamma-delta T cell therapies for cancer and viral infections, is currently conducting pivotal clinical trials for its therapies.

TC Biopharm (NASDAQ: TCBP) announced the appointment of four new independent members, Mark Bonyhadi, James Culverwell, Arlene Morris, and Edward Niemczyk, to its Board of Directors, effective post-IPO. This increases the board's membership to seven. The CEO, Bryan Kobel, expressed confidence in their leadership and expertise in drug commercialization and capital markets to drive the company's strategy in developing gamma-delta T cell therapies for cancer and viral infections.

TC Biopharm has successfully closed its initial public offering, raising approximately $17.5 million through the sale of 4,117,648 ADSs and warrants to purchase up to 8,235,296 ADSs. The offering included an additional 1,235,294 warrants purchased by underwriters at an exercise price of $4.25. The proceeds will finance clinical trials for OmnImmune® and ImmuniStim® therapies, designed to treat acute myeloid leukemia and COVID-19, respectively, alongside other operational and research costs.

TC BioPharm, a clinical stage biotechnology company, announces its American Depositary Shares will start trading on the Nasdaq under the ticker symbol TCBP as of February 11, 2022. This listing is a significant milestone, allowing the company greater access to capital markets and increased visibility. TC BioPharm focuses on developing gamma-delta T cell therapies for cancer and viral infections, with key products including OmnImmune^®, currently in late-stage clinical trials for blood cancer. The company aims to enhance shareholder value through this listing.